--- title: "Lp(a) Mail-In Test — Evidence, Benefits & Where to Buy | Magellan" description: "Lp(a) Mail-In Test — Lipoprotein(a), or Lp(a), is a low-density lipoprotein (LDL)-like particle in which an apolipoprotein(a) molecule is covalently…" url: "https://magellanlongevity.com/p/141.md" canonical: "https://magellanlongevity.com/p/141.html" html: "https://magellanlongevity.com/p/141.html" type: "product" section: "Diagnostics & Epigenetic Tests" evidence_grade: "Measurement tool" evidence_tier: "tool" citations: 19 product_id: 141 price_usd: 152 updated: 2026-09-02 author: "Gabriel Radu, DO" author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765." publisher: "Magellan Longevity" content_format: "markdown" license: "Educational content — not medical advice" --- # Lp(a) Mail-In Test [Home](https://magellanlongevity.com/) › [Diagnostics & Epigenetic Tests](https://magellanlongevity.com/c/2.md) › Lp(a) Mail-In Test **HTML version:** https://magellanlongevity.com/p/141.html · **In the Magellan app:** https://magellanlongevity.com/#/product/141 ## Key facts | Field | Value | | --- | --- | | Product | Lp(a) Mail-In Test | | Category | [Diagnostics & Epigenetic Tests](https://magellanlongevity.com/c/2.md) | | Evidence grade | Measurement tool (B) | | Peer-reviewed citations | 19 | | Typical listed price | $152.00 (check the live price) | | Where to buy | [Search Amazon](https://www.amazon.com/s?k=Lp%28a%29%20Mail-In%20Test&tag=magellanlong-20) | | Catalog ID | 141 | ## What it is Lipoprotein(a), or Lp(a), is a low-density lipoprotein (LDL)-like particle in which an apolipoprotein(a) molecule is covalently bound to apolipoprotein B-100. Its blood concentration is roughly 80–90% genetically determined by variation in the LPA gene and stays relatively stable across a person's lifetime, while differing widely between individuals and populations. An Lp(a) test measures this concentration, which is not captured by a standard cholesterol panel. Elevated Lp(a) promotes atherosclerosis, inflammation, and valve calcification, and major guidelines now recommend measuring it at least once in every adult's lifetime to flag very high inherited levels. ## Its role in longevity Large meta-analyses, prospective cohorts, and Mendelian randomization studies establish elevated Lp(a) as a causal, independent risk factor for coronary heart disease, myocardial infarction, ischemic stroke, peripheral artery disease, and calcific aortic valve stenosis, with roughly one in five people carrying high levels; very high levels carry risk comparable to heterozygous familial hypercholesterolemia. The association is continuous and largely independent of LDL cholesterol, although effect sizes for stroke and all-cause mortality are more modest. RNA-based therapies—and now a first oral inhibitor—lower Lp(a) by roughly 70–100% in trials, but cardiovascular outcome trials are still ongoing and no Lp(a)-specific drug is yet approved, so measuring it currently guides risk stratification more than treatment. This evidence concerns the Lp(a) biomarker and its measurement in general, not this specific commercial mail-in test. ## Evidence grade: Measurement tool - **What the grade means:** Graded as an instrument: how accurately it measures, and whether measuring it changes anything. - **Dose used in studies:** Once in adult life. Lp(a) is set by the LPA gene you were born with and moves very little afterwards, so one good result is the result. Repeat only if the units or the lab change and you cannot line the numbers up. - **What this grade does not say:** The analyte is about as solid as anything on this site: LPA gene variants that raise Lp(a) track coronary disease in a dose-dependent way, the European Atherosclerosis Society treats a raised level as an independent causal risk factor, and in the 30-year follow-up of the Women's Health Study a single baseline Lp(a) still carried predictive weight three decades on. But this is not a standalone Lp(a) test - it is a multi-analyte heart panel that also returns ApoB and hs-CRP, so it overlaps two other tests on this list, and Lp(a) reporting still has a real standardisation problem: mg/dL and nmol/L are not interchangeable, and apo(a) isoform size biases mass-based assays. The part the marketing skips is that there is no licensed Lp(a)-lowering drug today - olpasiran and its class lower the number impressively, but the cardiovascular outcome trials have not reported. So a high result changes only how hard you and a clinician manage everything else you can actually move, which is worth knowing once, because the number itself will not change. ## In the news - **The latest on lipoprotein(a), an inherited cause of early heart disease** — Harvard Health 2023 [Read it](https://www.health.harvard.edu/heart-health/the-latest-on-lipoprotein-a-an-inherited-cause-of-early-heart-disease) > A high Lp(a) level may double or even triple a person's risk of a heart attack. It also raises the risk of stroke and is linked to a narrowing of the aortic valve (aortic stenosis). - **Lipoprotein(a): Progress on One of the Last Untreatable Frontiers of Cardiovascular Risk** — Cleveland Clinic 2024 [Read it](https://consultqd.clevelandclinic.org/lipoproteina-progress-on-one-of-the-last-untreatable-frontiers-of-cardiovascular-risk) > Elevated Lp(a) is a genetically determined risk factor, and there is no evidence that Lp(a) level changes over the course of a lifetime. ## The research Peer-reviewed studies on the active compound. Quotes are verbatim from the cited abstract. Research describes the active mechanism and is not a claim about this specific product. ### Cited studies 1. **Evidence: Lipoprotein(a) concentration** JAMA 2009 · [PMID 19622820](https://pubmed.ncbi.nlm.nih.gov/19622820/) · [DOI 10.1001/jama.2009.1063](https://doi.org/10.1001/jama.2009.1063) > continuous, independent, and modest associations of Lp(a) concentration with risk of coronary heart disease and stroke 2. **Lipoprotein(a) and Cardiovascular Disease** Clin Chem 2021 · [PMID 33236085](https://pubmed.ncbi.nlm.nih.gov/33236085/) · [DOI 10.1093/clinchem/hvaa247](https://doi.org/10.1093/clinchem/hvaa247) > high lipoprotein(a) concentrations predict 2- to 3-fold increases in risk 3. **Elevated Lipoprotein(a) and Risk of Atrial Fibrillation** J Am Coll Cardiol 2022 · [PMID 35450575](https://pubmed.ncbi.nlm.nih.gov/35450575/) · [DOI 10.1016/j.jacc.2022.02.018](https://doi.org/10.1016/j.jacc.2022.02.018) > genetically predicted Lp(a) associated with an increased risk of incident atrial fibrillation 4. **Lipoprotein (a) and risk of cardiovascular disease--a systematic review and meta analysis of prospective studies.** Clin Lab 2011 · [PMID 21500721](https://pubmed.ncbi.nlm.nih.gov/21500721/) > This meta analysis of prospective studies shows a clear association between elevated Lipoprotein (a) levels and increased risk of CHD. This effect is substantially higher in individuals with previous CHD. Our systematic review showed no evidence of an effect on stroke and all cause mortality. 5. **Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis.** Circulation 2024 · [PMID 39492722](https://pubmed.ncbi.nlm.nih.gov/39492722/) · [DOI 10.1161/CIRCULATIONAHA.124.069556](https://doi.org/10.1161/CIRCULATIONAHA.124.069556) > These findings demonstrate the independent and additive nature of Lp(a) and LDL-C levels for ASCVD risk, and that LDL-C lowering does not fully offset Lp(a)-mediated risk. 6. **Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.** Lancet 2018 · [PMID 30293769](https://pubmed.ncbi.nlm.nih.gov/30293769/) · [DOI 10.1016/S0140-6736(18)31652-0](https://doi.org/10.1016/S0140-6736%2818%2931652-0) > In this individual-patient data meta-analysis of statin-treated patients, elevated baseline and on-statin lipoprotein(a) showed an independent approximately linear relation with cardiovascular disease risk. 7. **Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.** Eur Heart J 2022 · [PMID 36036785](https://pubmed.ncbi.nlm.nih.gov/36036785/) · [DOI 10.1093/eurheartj/ehac361](https://doi.org/10.1093/eurheartj/ehac361) > Epidemiologic and genetic studies involving hundreds of thousands of individuals strongly support a causal and continuous association between Lp(a) concentration and cardiovascular outcomes in different ethnicities; elevated Lp(a) is a risk factor even at very low levels of low-density lipoprotein cholesterol. 8. **Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations.** JAMA Cardiol 2024 · [PMID 38353970](https://pubmed.ncbi.nlm.nih.gov/38353970/) · [DOI 10.1001/jamacardio.2023.5605](https://doi.org/10.1001/jamacardio.2023.5605) > In this study, higher levels of Lp(a) were associated with MACE, MI, and PAD in both primary and secondary prevention populations regardless of baseline hs-CRP value. 9. **Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort.** J Am Coll Cardiol 2024 · [PMID 38631771](https://pubmed.ncbi.nlm.nih.gov/38631771/) · [DOI 10.1016/j.jacc.2024.02.031](https://doi.org/10.1016/j.jacc.2024.02.031) > The study shows, in a large U.S. pooled cohort, that higher Lp(a) levels are associated with an increased ASCVD risk, including in patients with diabetes. 10. **Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.** JAMA Cardiol 2018 · [PMID 29926099](https://pubmed.ncbi.nlm.nih.gov/29926099/) · [DOI 10.1001/jamacardio.2018.1470](https://doi.org/10.1001/jamacardio.2018.1470) > The clinical benefit of lowering Lp(a) is likely to be proportional to the absolute reduction in Lp(a) concentration. 11. **Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis.** Atherosclerosis 2015 · [PMID 26298741](https://pubmed.ncbi.nlm.nih.gov/26298741/) · [DOI 10.1016/j.atherosclerosis.2015.08.021](https://doi.org/10.1016/j.atherosclerosis.2015.08.021) > Elevated Lp(a) is an independent risk factor for ischemic stroke and may be especially relevant for young stroke patients. 12. **Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis.** Eur J Epidemiol 2023 · [PMID 36708412](https://pubmed.ncbi.nlm.nih.gov/36708412/) · [DOI 10.1007/s10654-022-00956-4](https://doi.org/10.1007/s10654-022-00956-4) > This study provides further evidence that higher Lp(a) levels are associated with higher risk of all-cause mortality and CVD-death in the general population and in patients with CVD. 13. **Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.** N Engl J Med 2022 · [PMID 36342163](https://pubmed.ncbi.nlm.nih.gov/36342163/) · [DOI 10.1056/NEJMoa2211023](https://doi.org/10.1056/NEJMoa2211023) > Olpasiran therapy significantly reduced lipoprotein(a) concentrations in patients with established atherosclerotic cardiovascular disease. Longer and larger trials will be necessary to determine the effect of olpasiran therapy on cardiovascular disease. 14. **LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics.** Annu Rev Pharmacol Toxicol 2023 · [PMID 37506332](https://pubmed.ncbi.nlm.nih.gov/37506332/) · [DOI 10.1146/annurev-pharmtox-031023-100609](https://doi.org/10.1146/annurev-pharmtox-031023-100609) > Approximately 20% of the world's population has increased Lp(a) levels, determined predominantly by genetics. Current clinical practices for the management of dyslipidemia are ineffective in lowering Lp(a) levels. 15. **A common LPA null allele associates with lower lipoprotein(a) levels and coronary artery disease risk.** Arterioscler Thromb Vasc Biol 2014 · [PMID 24925971](https://pubmed.ncbi.nlm.nih.gov/24925971/) · [DOI 10.1161/ATVBAHA.114.303462](https://doi.org/10.1161/ATVBAHA.114.303462) > The LPA null allele (rs41272114) is associated with decreased circulating lipoprotein(a) levels and decreased CAD risk. 16. **Structure, function, and genetics of lipoprotein (a).** J Lipid Res 2016 · [PMID 27074913](https://pubmed.ncbi.nlm.nih.gov/27074913/) · [DOI 10.1194/jlr.R067314](https://doi.org/10.1194/jlr.R067314) > It highlights the role of genetics in establishing Lp(a) as a risk factor for CHD, but also discusses uncertainties, controversies, and lack of knowledge on several aspects of the genetic Lp(a) trait, not least its function. 17. **Genetics of the Lp(a)/apo(a) system in an autochthonous Black African population from the Gabon.** Eur J Hum Genet 2006 · [PMID 16267501](https://pubmed.ncbi.nlm.nih.gov/16267501/) · [DOI 10.1038/sj.ejhg.5201512](https://doi.org/10.1038/sj.ejhg.5201512) > Our data demonstrate that Lp(a) concentrations are highly heritable in a Central African population without admixture and high Lp(a) (median 43 mg/dl). LPA is the major QTL, explaining most or all of the heritability of Lp(a) in this population. 18. **Calcific aortic stenosis.** Nat Rev Dis Primers 2016 · [PMID 27188578](https://pubmed.ncbi.nlm.nih.gov/27188578/) · [DOI 10.1038/nrdp.2016.6](https://doi.org/10.1038/nrdp.2016.6) > Metabolic syndrome and an elevated plasma level of lipoprotein(a) have also been associated with increased risk of calcific AS. 19. **Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial.** JAMA 2025 · [PMID 39556768](https://pubmed.ncbi.nlm.nih.gov/39556768/) > Randomized trial: the first oral small-molecule Lp(a) inhibitor muvalaplin lowered Lp(a), showing a needle-free option is feasible. ## Where to buy [Search Amazon for Lp(a) Mail-In Test](https://www.amazon.com/s?k=Lp%28a%29%20Mail-In%20Test&tag=magellanlong-20) — affiliate search link. ## Structured data ```json {"@context":"https://schema.org","@graph":[{"@type":"ItemPage","@id":"https://magellanlongevity.com/p/141.html#page","url":"https://magellanlongevity.com/p/141.html","name":"Lp(a) Mail-In Test","description":"Lipoprotein(a), or Lp(a), is a low-density lipoprotein (LDL)-like particle in which an apolipoprotein(a) molecule is covalently bound to apolipoprotein…","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/p/141.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Diagnostics & Epigenetic Tests","item":"https://magellanlongevity.com/c/2.html"},{"@type":"ListItem","position":3,"name":"Lp(a) Mail-In Test","item":"https://magellanlongevity.com/p/141.html"}]},{"@type":"Product","@id":"https://magellanlongevity.com/p/141.html#product","name":"Lp(a) Mail-In Test","category":"Diagnostics & Epigenetic Tests","url":"https://magellanlongevity.com/p/141.html","description":"Lipoprotein(a), or Lp(a), is a low-density lipoprotein (LDL)-like particle in which an apolipoprotein(a) molecule is covalently bound to apolipoprotein B-100. Its blood concentration is roughly 80–90% genetically determined by variation in the LPA gene and stays relatively stable across a person's…","additionalProperty":[{"@type":"PropertyValue","name":"Evidence grade","value":"Measurement tool"}],"offers":{"@type":"Offer","priceCurrency":"USD","price":"152.00","url":"https://www.amazon.com/s?k=Lp%28a%29%20Mail-In%20Test&tag=magellanlong-20","availability":"https://schema.org/InStock"}}]} ``` ## Related on Magellan Longevity - [Grip-Strength Dynamometer](https://magellanlongevity.com/p/153.md) — Across large prospective cohorts and meta-analyses, lower grip strength is consistently associated with… - [Saliva Cortisol Stress Test](https://magellanlongevity.com/p/149.md) — Across large studies, dysregulated cortisol patterns track with worse health: a meta-analysis found flatter… - [GGT Liver-Health Test](https://magellanlongevity.com/p/156.md) — Large prospective cohorts and meta-analyses consistently link higher serum GGT, even within the reference… - [Fasting Insulin / HOMA-IR Kit](https://magellanlongevity.com/p/145.md) — Higher fasting insulin and HOMA-IR reflect greater insulin resistance, a central feature of metabolic… - [hs-CRP Inflammation Test](https://magellanlongevity.com/p/142.md) — Across large prospective cohorts and meta-analyses, higher hs-CRP is consistently associated with increased… - [All Diagnostics & Epigenetic Tests](https://magellanlongevity.com/c/2.md) - [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md) - [Longevity research map](https://magellanlongevity.com/longevity-research-map.html) ## Scope and disclosures Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication. Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases. Reviewed for accuracy by a board-certified physician (DO).